Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012

   Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late
 Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting

PR Newswire

HAYWARD, Calif., Nov. 1, 2012

HAYWARD, Calif., Nov.1, 2012 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious
diseases associated with inflammation and autoimmune disorders, today
announced that an abstract of the results from the Phase 2b PEARL-SC clinical
study examining the treatment effect of blisibimod in systemic lupus
erythematosus patients has been accepted as a late-breaking poster
presentation at the 2012 Annual Scientific Meeting of the American College of
Rheumatology and the Association of Rheumatology Health Professionals
(ACR/ARHP).

"We are pleased to have this opportunity to share the PEARLS-SC responder
analyses and sub-population results with the rheumatology community," said
Colin Hislop, MD, Anthera's Senior Vice President and Chief Medical Officer.
"In PEARL-SC, blisibimod demonstrated a clinically meaningful treatment effect
in patients with severe disease who continued to have active lupus despite
corticosteroid use. This highlights blisibimod's potential to help patients
with more active and severe disease as we move forward with our Phase 3
clinical trials."

The poster entitled, "Blisibimod, an Inhibitor of B Cell Activating Factor, in
Patients with Moderate-to-Severe Systemic Lupus Erythematosus," is scheduled
to be presented by Dr. Richard Furie on Tuesday, November 13, from 9 am – 11
am Eastern Time (Presentation Number L6).

The abstract is available online through the ACR website at
www.rheumatology.org. In accordance with the conference's embargo policy, the
poster will be uploaded to the Anthera website only after completion of the
session.

About Blisibimod and PEARL-SC
BAFF has been associated with a wide range of B-cell-mediated autoimmune
diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy,
immune thrombocytopenic purpura and others. Multiple clinical studies with
other BAFF antagonists recently have reported on BAFF's potential positive
role in treating lupus and rheumatoid arthritis. Anthera is advancing its
development of blisibimod, a broad inhibitor of BAFF, to expand its potential
clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein
called a peptibody and is distinct from an antibody. Anthera owns worldwide
rights to blisibimod in all potential indications. The PEARL-SC Phase 2 study
was designed as a randomized, double-blind, placebo-controlled, dose-ranging
superiority trial to evaluate the safety, tolerability and efficacy of
blisibimod plus standard of care, versus placebo plus standard of care. A
total of 547 patients with active SLE were randomized to receive one of three
different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200
mg monthly) administered subcutaneously over a minimum 24-week treatment
period, in addition to standard-of-care therapy. The study was conducted at
multiple centers worldwide.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement
Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on Anthera's expectations as of the date of this press
release and are subject to certain risks and uncertainties that could cause
actual results to differ materially as set forth in Anthera's public filings
with the SEC, including Anthera's Annual Report on Form 10-K for the year
ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter
ended June 30, 2012. Anthera disclaims any intent or obligation to update any
forward-looking statements, whether because of new information, future events
or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or
510.856.5586.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com
Website: http://www.rheumatology.org
 
Press spacebar to pause and continue. Press esc to stop.